TPIDB > 臨床試驗主持人
臨床試驗主持人
更新時間：2023-09-19
成佳憲Chen, Chia-Hsien
- 計畫主持人
- 執行臨床試驗年資 12 年 9 個月
發表文獻
95筆
11
Tsai CL, Cheng JC*. Evolving development of multi-parametric normal tissue complication probability model for liver radiotherapy. Translational Cancer Research 8(Suppl 2): S120-S123, 2019 (Editorial)
12
Lu SL, Hsu FM, Tsai CL, Lee JM, Huang PM, Hsu CH, Lin CC, Chang YL, Hsieh MS, Cheng JC*. Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: Hypothesis generating for adjuvant treatment. European Journal of Surgical Oncology 45:1498-1504, 2019 (SCI)
13
Tsai CL, Liu WL, Hsu FM, Yang PS, Yen RF, Tzen KY, Cheng AL, Chen PJ, Cheng JC*. Targeting histone deacetylase 4/Ubc9 impairs DNA repair for radiosensitization of hepatocellular carcinoma cells. Hepatology 67:586-599, 2018 (SCI)
14
Hou WH, Huang CY, Wang CC, Lan KH, Chen CH, Yu HJ, Liu SP, Lai MK, Pu YS, Cheng JC*. Impact of androgen-deprivation therapy on the outcome of dose-escalation prostate cancer radiotherapy without elective pelvic irradiation. Asian Journal of Andrology 19:596-601, 2017 (SCI)
15
Liang JT, Chen TC, Huang J, Jeng YM, Cheng JC*. Treatment outcomes regarding the addition of targeted agents in the therapeutic portfolio for stage II-III rectal cancer undergoing neoadjuvant chemoradiation. Oncotarget 8;101832-101846, 2017
16
Wang YJ, Huang CY, Hou WH, Wang CC, Lan KH, Yu HJ, Lai MK, Liu SP, Pu YS, Cheng JC*. Dual-timing PSA as a biomarker for patients with salvage intensity modulated radiation therapy for biochemical failure after radical prostatectomy. Oncotarget 7:44224-44235, 2016
17
Tsai CL, Hsu FM, Cheng JC*. How to improve therapeutic ratio in radiotherapy of HCC. Liver Cancer 5:210-220, 2016 (SCI)
18
Hou WH, Wang CW, Tsai CL, Hsu FM, Cheng JC*. The ratio of weight loss to planning target volume significantly impacts setup errors in nasopharyngeal cancer patients undergoing helical tomotherapy with daily megavoltage computed tomography. Radiology and Oncology 50:427-432, 2016 (SCI)
19
Hsu FM, Hou WH, Huang CY, Wang CC, Tsai CL, Tsai YC, Yu HJ, Pu YS*, Cheng JC*. Differences in toxicity and outcome associated with circadian variations between patients undergoing daytime and evening radiotherapy for prostate adenocarcinoma. Chronobiology International 33:210-219, 2016 (SCI)
20
Lu SL, Hsu FM, Chen KY, Ho CC, Yang JC, Cheng JC*. Maximizing benefits from maintenance pemetrexed with stereotactic ablative radiotherapy in oligoprogressive non-squamous non-small cell lung cancer. Case Reports in Oncology 9:474-480, 2016
